Tomorrow, the American public will get a fresh glimpse at the state of the US labor market. The Bureau of Labor Statistics’ (BLS) release of the September employment report, which will be the next-to-last before the upcoming election, will provide voters new insight on job growth and unemployment rates.
As Brill sees it, there are 4 main categories of barriers to biosimilar uptake: reference product manufacturers, biosimilar manufacturers, policy, and education.
In a new paper, MGA discusses why the biosimilars market in the United States is not more developed and what steps can be taken to boost competition for biologic drugs. The paper identifies barriers to biosimilars by four categories, related to reference product manufacturers, biosimilar manufacturers, policy, and stakeholder education and awareness. Among the strategies to overcoming barriers are more physician and patient education, competitive biosimilar pricing, action by employer-sponsored health plans and private payors to encourage biosimilar utilization, and continued FDA efforts to support the budding market.
A new study from MGA examines the practice by brand drug manufacturers of using Risk Evaluation and Mitigation Strategies (REMS) and other forms of restricted access to keep generic manufacturers from obtaining samples needed to develop generic drugs. MGA estimates that this misuse blocks $13.4 billion in generic savings annually, an estimate that has grown nearly 250 percent since MGA’s 2014 analysis of this issue.
In the ‘Something More with Chris Boyd’ interview, Brill discusses the state of the economy.
